Produkt: TNF-α human ELISA
TNF-α human ELISA
: 96 determinations
: serum, plasma (EDTA, heparin), cell culture
: 50 µl
: 31 - 1000 pg/ml
: 120, 60 (RT), 20 min (RT/dark)
: TMB at 450 nm
: 7 pg/ml
Tumor necrosis factor- α (TNF- α) is a pleiotropic inflammatory cytokine. Most organs of the body appear to be affected by TNF-α, and the cytokine serves a variety of functions. The cytokine possesses both growth stimulating properties and growth inhibitory processes, and it appears to have self regulatory properties as well. TNFα circulates throughout the body responding to stimuli (infectious agents or tissue injury); activating neutrophils; altering the properties of vascular endothelial cells; regulating metabolic activities of other tissues as well as exhibiting tumoricidal activity by inducing localized blood clotting. TNF-α also inhibits lipoprotein lipase activity resulting in cachexia, a physical wasting condition. Activation of B-cells by the Epstein Barr virus can be inhibited by TNFα. Due to its varied actions throughout the immune system, TNF-α may play a role in the pathogenesis of many disease states.
Since TNF-α plays a role in several diseases, a substantial amount of research has been conducted concerning TNF-α therapies and anti-TNF-α therapies. As TNF-α exhibits anti tumor activity, research has been conducted to determine the protein's effectiveness against certain forms of cancers. Utilizing TNF-α tumoricidal activities has proved problematic, especially due to the cytotoxin's systematic toxicity.
Measurement of TNF-α levels has also been shown to be useful in transplant research, TNFα to be markedly elevated in renal allograft rejection episodes. Recent evidence has been presented on increased TNFα levels in Bone Marrow Transplant (BMT). BMT patients with major transplant related complications such as interstitial pneumonitis and severe acute graft-versus-host disease had TNFα levels significantly increase over controls.
The DEMEDITEC Human TNF-α ELISA is a sandwich assay for the determination of TNF-α in serum, plasma and cell culture supernatants. During the first incubation period TNF-α in patient serum/plasma samples are captured by the monoclonal antibody to human TNF-α coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled second monoclonal antibody conjugate is added to each well and then incubated. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction color is directly proportional to the concentration of human TNF-α in sample.